The case for & against
Bull & Bear analysis
Bullish
Philip Morris International Inc. (NYSE: PM) is a leading player in the global tobacco industry, transitioning towards a future focused on smoke-free products, notably its IQOS heat-not-burn technology and Zyn nicotine pouches. The company holds a dominant position in the tobacco market, leveraging its extensive distribution networks and brand recognition. With an ongoing commitment to reduce the harmful effects of smoking, PMI is well-positioned to capitalize on the growing trend of consumer preference for less harmful alternatives, aligning with the global health shift towards reduced tobacco harm.
Bull says
- ↑Q1 2024 EPS $1.96 vs est. $1.83; revenue up 9.1% YoY to $10.15 B
- ↑FDA grants MRTP status to 20 Zyn products, boosting smoke-free adoption
- ↑Analyst consensus ‘Moderate Buy’ with $192.88 average price target
- ↑Maintained quarterly dividend of $1.47, signaling strong cash flow
- ↑High Book-to-Price ratio and momentum in reduced-risk segment
- ↑High sensitivity to oil prices could improve margins in rising commodity environment
Bear says
- ↓Negative earnings yield and weak profitability metrics hinder returns
- ↓Deteriorating analyst revisions suggest growth expectations may falter
- ↓High leverage ratio increases financial risk in a rising-rate environment
- ↓Ongoing regulatory scrutiny and combustible reliance may limit appeal
- ↓Scale disadvantages and volatility risks expose value-trap potential
- ↓Negative profitability and revision trends underscore operational challenges
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 07-02-2026neutral
Transcript signals
Bull points
- EMPEROR platform is designed to address this. It's smaller device profile, which broadens patients' eligibility, including women, and smaller frame patients who are currently excluded from a TH therapy.
- The EMPEROR platform is designed to address this. It's smaller device profile, which broadens patients' eligibility, including women, and smaller frame patients who are currently excluded from a TH therapy.
- Since November of 2024, we've implanted five total artificial heart devices. Two of the five patients moved forward with successful heart transplant, one is awaiting discharge from the hospital, and two have passed away, which our outcomes indicate a robust center of excellence.
Bear points
- Post-LVAD right ventricular failure occurs in 20% to 40% of cases, and that's not a marginal number. That is a substantial portion of our patient population for whom we do not have an approved curable solution.
- the device is right now only approved for patients as a bridge to heart transplant
- Our GAAP loss for 2025 was approximately $27 million, which includes non-cash and financing related items such as derivative accounting and amortization of debt discounts and other financing related charges.
Read full transcript analysis ›